AlphaStreet Newsdesk powered by AlphaStreet Intelligence
KURA|EPS -$0.78 vs -$0.81 est (+3.7%)|Rev $22.8M vs $23.9M est (-4.4%)|Net Loss $70.2MKura Oncology, Inc. reported a narrower quarterly loss for the third quarter of 2026, posting a loss of $0.78 per share compared to the $0.81 loss anticipated by analysts, beating expectations by 3.7%. The clinical-stage biopharmaceutical company, which develops cancer treatments, recorded a net loss of $70.2M for the quarter. The per-share loss narrowed 8.2% from the $0.85 loss reported in Q3 2025, reflecting improved cost management as the company advances its oncology pipeline.
Revenue came in at $22.8M, falling 4.4% short of the $23.9M consensus estimate from Wall Street analysts. The company posted a 10.1% increase in revenue from the $20.8M recorded in the year-ago quarter. The revenue growth signals continued commercial traction for Kura’s treatments in the competitive oncology market.
Operational metrics showed the company recorded 150 new patient starts during the quarter, while total prescriptions reached 420 at quarter-end. These prescription trends provide insight into the real-world adoption of Kura’s therapeutic offerings as the company works to expand its market presence.
Analyst sentiment remains predominantly bullish on the stock, with Wall Street consensus standing at 13 buy ratings, 3 hold ratings, and zero sell recommendations. The strong analyst support reflects confidence in Kura’s development strategy and its potential to advance treatments for cancer patients.
This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.
AlphaStreet Newsdesk powered by AlphaStreet Intelligence
KURA|EPS -$0.78 vs -$0.81 est (+3.7%)|Rev $22.8M vs $23.9M est (-4.4%)|Net Loss $70.2MKura Oncology, Inc. reported a narrower quarterly loss for the third quarter of 2026, posting a loss of $0.78 per share compared to the $0.81 loss anticipated by analysts, beating expectations by 3.7%. The clinical-stage biopharmaceutical company, which develops cancer treatments, recorded a net loss of $70.2M for the quarter. The per-share loss narrowed 8.2% from the $0.85 loss reported in Q3 2025, reflecting improved cost management as the company advances its oncology pipeline.
Revenue came in at $22.8M, falling 4.4% short of the $23.9M consensus estimate from Wall Street analysts. The company posted a 10.1% increase in revenue from the $20.8M recorded in the year-ago quarter. The revenue growth signals continued commercial traction for Kura’s treatments in the competitive oncology market.
Operational metrics showed the company recorded 150 new patient starts during the quarter, while total prescriptions reached 420 at quarter-end. These prescription trends provide insight into the real-world adoption of Kura’s therapeutic offerings as the company works to expand its market presence.
Analyst sentiment remains predominantly bullish on the stock, with Wall Street consensus standing at 13 buy ratings, 3 hold ratings, and zero sell recommendations. The strong analyst support reflects confidence in Kura’s development strategy and its potential to advance treatments for cancer patients.
This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.
